Literature DB >> 18820717

Lipodystrophy and quality of life of HIV-infected persons.

Giovanni Guaraldi1, Rita Murri, Gabriella Orlando, Nicola Squillace, Chiara Stentarelli, Stefano Zona, Elisa Garlassi, Esteban Martínez.   

Abstract

Morphological changes induced by HIV-related lipodystrophy profoundly affect body image and influence health-related quality of life. Measurements of health-related quality of life in patients with lipodystrophy are complex due to a lack of consensus on the definition of lipodystrophy, a lack of appropriate methods to capture the impact of body fat changes, and the subjective perception of those changes by patients. This review describes the different tools that have been used to assess quality of life in patients with lipodystrophy, and critically analyzes published papers on health-related quality of life. With regard to facial lipoatrophy, the most stigmatizing condition of lipodystrophy, we have analyzed the impact of reconstructive plastic surgery on patient-related outcomes and health-related quality of life. A better knowledge of the associations between lipodystrophy and health-related quality of life will allow us to understand the burden of long-term toxicities of antiretroviral therapies as well as to identify novel patient-related endpoints useful in assessing the efficacy of lipodystrophy treating programs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820717

Source DB:  PubMed          Journal:  AIDS Rev        ISSN: 1139-6121            Impact factor:   2.500


  16 in total

1.  Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).

Authors:  N Sunil Kumar; J Shashibhushan; K Venugopal; Huggi Vishwanatha; Mahesh Menon
Journal:  J Clin Diagn Res       Date:  2015-07-01

2.  Assessing appearance-related disturbances in HIV-infected men who have sex with men (MSM): psychometrics of the body change and distress questionnaire-short form (ABCD-SF).

Authors:  Aaron J Blashill; Johannes M Wilson; Joshua S Baker; Kenneth H Mayer; Steven A Safren
Journal:  AIDS Behav       Date:  2014-06

Review 3.  Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 4.  HIV-associated lipodystrophy: impact of antiretroviral therapy.

Authors:  Giovanni Guaraldi; Chiara Stentarelli; Stefano Zona; Antonella Santoro
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 5.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

6.  Lipodystrophy and inflammation predict later grip strength in HIV-infected men: the MACS Body Composition substudy.

Authors:  Keith W Crawford; Xiuhong Li; Xiaoqiang Xu; Alison G Abraham; Adrian S Dobs; Joseph B Margolick; Frank J Palella; Lawrence A Kingsley; Mallory D Witt; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-02       Impact factor: 2.205

Review 7.  Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection.

Authors:  Kristine M Erlandson; Jordan E Lake
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

8.  Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study.

Authors:  Vichet Phan; Sopheak Thai; Kimcheng Choun; Lutgarde Lynen; Johan van Griensven
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

9.  New and emerging agents in the management of lipodystrophy in HIV-infected patients.

Authors:  Eric Bonnet
Journal:  HIV AIDS (Auckl)       Date:  2010-09-17

10.  A Randomized Comparison of Anthropomorphic Changes With Preferred and Alternative Efavirenz-Based Antiretroviral Regimens in Diverse Multinational Settings.

Authors:  Kristine M Erlandson; Sineenart Taejaroenkul; Laura Smeaton; Amita Gupta; Isaac L Singini; Javier R Lama; Rosie Mngqibisa; Cynthia Firnhaber; Sandra Wagner Cardoso; Cecilia Kanyama; Andre L Machado da Silva; James G Hakim; Nagalingeswaran Kumarasamy; Thomas B Campbell; Michael D Hughes
Journal:  Open Forum Infect Dis       Date:  2015-06-24       Impact factor: 3.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.